417 related articles for article (PubMed ID: 28093104)
1. Faecal shedding of canine parvovirus after modified-live vaccination in healthy adult dogs.
Freisl M; Speck S; Truyen U; Reese S; Proksch AL; Hartmann K
Vet J; 2017 Jan; 219():15-21. PubMed ID: 28093104
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with canine parvovirus type 2 (CPV-2) protects against challenge with virulent CPV-2b and CPV-2c.
Siedek EM; Schmidt H; Sture GH; Raue R
Berl Munch Tierarztl Wochenschr; 2011; 124(1-2):58-64. PubMed ID: 21306055
[TBL] [Abstract][Full Text] [Related]
3. Long-term viremia and fecal shedding in pups after modified-live canine parvovirus vaccination.
Decaro N; Crescenzo G; Desario C; Cavalli A; Losurdo M; Colaianni ML; Ventrella G; Rizzi S; Aulicino S; Lucente MS; Buonavoglia C
Vaccine; 2014 Jun; 32(30):3850-3. PubMed ID: 24793948
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of positive antibody test results for canine parvovirus (CPV) and canine distemper virus (CDV) and response to modified live vaccination against CPV and CDV in dogs entering animal shelters.
Litster A; Nichols J; Volpe A
Vet Microbiol; 2012 May; 157(1-2):86-90. PubMed ID: 22261239
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of antibodies to canine parvovirus and reaction to vaccination in client-owned, healthy dogs.
Riedl M; Truyen U; Reese S; Hartmann K
Vet Rec; 2015 Dec; 177(23):597. PubMed ID: 26514756
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic Challenges in Canine Parvovirus 2c in Vaccine Failure Cases.
Yip HYE; Peaston A; Woolford L; Khuu SJ; Wallace G; Kumar RS; Patel K; Ahani Azari A; Akbarzadeh M; Sharifian M; Amanollahi R; Jafari Jozani R; Khabiri A; Hemmatzadeh F
Viruses; 2020 Sep; 12(9):. PubMed ID: 32899378
[TBL] [Abstract][Full Text] [Related]
7. Canine parvovirus type 2 vaccine protects against virulent challenge with type 2c virus.
Spibey N; Greenwood NM; Sutton D; Chalmers WS; Tarpey I
Vet Microbiol; 2008 Apr; 128(1-2):48-55. PubMed ID: 18006253
[TBL] [Abstract][Full Text] [Related]
8. MT-PCR panel detection of canine parvovirus (CPV-2): Vaccine and wild-type CPV-2 can be difficult to differentiate in canine diagnostic fecal samples.
Meggiolaro MN; Ly A; Rysnik-Steck B; Silva C; Zhang J; Higgins DP; Muscatello G; Norris JM; Krockenberger M; Šlapeta J
Mol Cell Probes; 2017 Jun; 33():20-23. PubMed ID: 28254505
[TBL] [Abstract][Full Text] [Related]
9. Do two current canine parvovirus type 2 and 2b vaccines provide protection against the new type 2c variant?
Larson LJ; Schultz RD
Vet Ther; 2008; 9(2):94-101. PubMed ID: 18597247
[TBL] [Abstract][Full Text] [Related]
10. Oral administration of modified live canine parvovirus type 2b induces systemic immune response.
Cavalli A; Desario C; Marinaro M; Losurdo M; Camero M; Decaro N; Catella C; Lanave G; Buonavoglia C
Vaccine; 2020 Jan; 38(2):115-118. PubMed ID: 31628031
[TBL] [Abstract][Full Text] [Related]
11. Comparison of selected canine vaccines for their ability to induce protective immunity against canine parvovirus infection.
Larson LJ; Schultz RD
Am J Vet Res; 1997 Apr; 58(4):360-3. PubMed ID: 9099379
[TBL] [Abstract][Full Text] [Related]
12. Intranasal vaccination of pups with maternally derived antibodies with a modified live canine parvovirus.
Buonavoglia C; Cavalli A; Gravino E; Voigt V; Buonavoglia D; de Caprariis D
Zentralbl Veterinarmed B; 1994 Mar; 41(1):3-8. PubMed ID: 7941844
[TBL] [Abstract][Full Text] [Related]
13. Antibody levels and protection to canine parvovirus type 2.
Elia G; Cavalli A; Cirone F; Lorusso E; Camero M; Buonavoglia D; Tempesta M
J Vet Med B Infect Dis Vet Public Health; 2005; 52(7-8):320-2. PubMed ID: 16316392
[TBL] [Abstract][Full Text] [Related]
14. Are vaccine strain, type or administration protocol risk factors for canine parvovirus vaccine failure?
Altman KD; Kelman M; Ward MP
Vet Microbiol; 2017 Oct; 210():8-16. PubMed ID: 29103701
[TBL] [Abstract][Full Text] [Related]
15. Vaccination of dogs with canine parvovirus type 2b (CPV-2b) induces neutralising antibody responses to CPV-2a and CPV-2c.
Wilson S; Illambas J; Siedek E; Stirling C; Thomas A; Plevová E; Sture G; Salt J
Vaccine; 2014 Sep; 32(42):5420-4. PubMed ID: 25148778
[TBL] [Abstract][Full Text] [Related]
16. Faecal shedding of parvovirus deoxyribonucleic acid following modified live feline panleucopenia virus vaccination in healthy cats.
Bergmann M; Schwertler S; Speck S; Truyen U; Reese S; Hartmann K
Vet Rec; 2019 Jul; 185(3):83. PubMed ID: 31040216
[TBL] [Abstract][Full Text] [Related]
17. Immunization of pups with maternally derived antibodies to canine parvovirus (CPV) using a modified-live variant (CPV-2b).
Pratelli A; Cavalli A; Normanno G; De Palma MG; Pastorelli G; Martella V; Buonavoglia C
J Vet Med B Infect Dis Vet Public Health; 2000 May; 47(4):273-6. PubMed ID: 10861195
[TBL] [Abstract][Full Text] [Related]
18. Self-assembly of virus-like particles of canine parvovirus capsid protein expressed from Escherichia coli and application as virus-like particle vaccine.
Xu J; Guo HC; Wei YQ; Dong H; Han SC; Ao D; Sun DH; Wang HM; Cao SZ; Sun SQ
Appl Microbiol Biotechnol; 2014 Apr; 98(8):3529-38. PubMed ID: 24413974
[TBL] [Abstract][Full Text] [Related]
19. Influence of clinical and laboratory variables on faecal antigen ELISA results in dogs with canine parvovirus infection.
Proksch AL; Unterer S; Speck S; Truyen U; Hartmann K
Vet J; 2015 Jun; 204(3):304-8. PubMed ID: 25920770
[TBL] [Abstract][Full Text] [Related]
20. Intranasal vaccination of pups in the presence of maternally derived antibodies to canine parvovirus (CPV). Evaluation of minimal immunizing dose.
Buonavoglia C; Cavalli A; Tempesta M; Voight V; Buonavoglia D; Corrente M; Sagazio P
New Microbiol; 1995 Oct; 18(4):371-5. PubMed ID: 8590389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
